Premium
Phathom Pharmaceuticals Inc (PHAT)
NASDAQ
Hot Features
Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small molecule potassium competitive acid blocker medicine that ... Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.285 | -4.7068538398 | 6.055 | 6.21 | 5.495 | 953239 | 5.71464315 | CS |
| 4 | -1.38 | -19.3006993007 | 7.15 | 7.25 | 5.21 | 1027599 | 5.95626213 | CS |
| 12 | -3.13 | -35.1685393258 | 8.9 | 9.79 | 5.21 | 983304 | 7.10813742 | CS |
| 26 | -7.12 | -55.236617533 | 12.89 | 19.675 | 5.21 | 1162879 | 11.82648046 | CS |
| 52 | -4.16 | -41.8932527694 | 9.93 | 19.675 | 5.21 | 938153 | 11.36910779 | CS |
| 156 | -12.28 | -68.0332409972 | 18.05 | 19.675 | 5.21 | 551341 | 10.66925241 | CS |
| 260 | -37.24 | -86.584515229 | 43.01 | 64.54 | 5.21 | 369677 | 13.18052055 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
